1020 First Avenue
King of Prussia
About CSL Behring
As the third largest global biotechnology company with employees in more than 35 countries, CSL Behring is focused on serving patients with serious and rare diseases, including coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and neurological disorders. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research.
CSL Behring's dynamic environment fosters innovation and attracts the best and brightest who share a commitment to helping save lives. People here are free to live their Promising FUTURES where they can fulfill their individual career aspirations and realize their potential.
CSL Behring is committed to diversity and inclusion, both of which underpin our Values of patient focus, innovation, collaboration, integrity and superior performance. We believe that by harnessing and honoring the unique capabilities, experiences and perspectives of our people, we are better able to serve our patients.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and provides its life-saving medicines in more than 70 countries.
For more information visit www.cslbehring.com. Help us deliver on our promise to save lives and protect the health of people around the world. Promising FUTURES start at CSL Behring!
Stock Symbol: CSL
Stock Exchange: Australian Securities Exchange
An overview of the CSL Behring Fermentation Facility at Penn State
286 articles with CSL Behring
CSL Behring Release: Many Rare Disease Patients Would Not Have Treatments Available To Them Without An Adequate Supply Of Human Plasma
FDA Accepts CSL Behring's Biologics License Application For First Subcutaneous Prophylactic Therapy To Prevent Hereditary Angioedema Attacks
CSL Behring Presents Pivotal Efficacy Data For AFSTYLA In Adolescents And Children With Hemophilia A At The World Federation Of Hemophilia 2016 World Congress
CSL Behring Presents Phase III Data For IDELVION For Hemophilia B At The World Federation of Hemophilia 2016 World Congress
CSL Behring Awards Emerging Coagulation Specialists Across The Globe To Support Advancements In The Care Of Patients With Bleeding Disorders
CSL Behring To Present New Data For IDELVION And AFSTYLA At The World Federation of Hemophilia 2016 World Congress
U.S. FDA Approves CSL Behring's Berinert As The First And Only Pediatric Treatment For Hereditary Angioedema (HAE)
AFSTYLA - CSL Behrings Novel Recombinant Factor VIII Single Chain Therapy For Hemophilia A - Now Available In The U.S.
U.S. FDA Approves CSL Behring's AFSTYLA-- The First And Only Recombinant Factor VIII Single Chain Therapy For Hemophilia A
European Commission (EC) Approves IDELVION --CSL Behring's Novel Hemophilia B Treatment With Up To 14-Day Dosing Intervals
CSL Behring Commemorates 100 Years Of Delivering On Its Promise To Develop Innovative Therapies For People With Life-Threatening Medical Conditions
CSL Behring Marks World Hemophilia Day By Donating Ius Of Its Specialty Biotherapeutics For Bleeding Disorders To World Federation Of Hemophilia
Albumedix Drug Delivery Technology Used By CSL Behring To Achieve 14 Day Dosing For Hemophilia B Therapy